8 April 2021
End of Quarter Review – March 2021
After a year of unprecedented challenges from the coronavirus (COVID-19) spread around the world and large swings in investor sentiment globally, the March 2021 quarter was noteworthy for renewed hope and optimism as the global COVID-19 case rate decreased and viable COVID vaccines began to be rolled out worldwide with bio-medical companies scaling-up production to meet demand.
